Tazeen Ahmad is a Managing Director in US Equity Research covering small and mid-cap Biotechnology. She joined the firm in 2009 as an associate on the large-cap pharmaceuticals team and transitioned to biotech in 2010. She assumed the role of senior SMID Biotech analyst in 2015. She has consistently ranked at the top of the Extel All-America Research poll in Biotechnology Small & Midcap since 2017, most recently as the #3-ranked analyst team in the 2024 poll. Previously, she was an associate at Citigroup on the large-cap pharma team. She has a bachelor’s degree in biology from Harvard University and is based in New York. For more information about any awards cited, visit https://rsch.baml.com/awards.